# OnCo record paper-portec-3-molecular-leon-castillo-jco-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-portec-3-molecular-leon-castillo-jco-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-portec-3-molecular-leon-castillo-jco-2020" ;
  schema:name "Molecular classification of the PORTEC-3 trial: prognosis and benefit from adjuvant chemotherapy by molecular group"@en ;
  schema:description "Re-analysing the PORTEC-3 trial by molecular class showed that p53-abnormal endometrial cancers gained substantially from adding chemotherapy to radiotherapy, POLE-mutated tumours did well regardless, and the other groups gained little."@en ;
  schema:url <https://onco.cc/key-papers/paper-portec-3-molecular-leon-castillo-jco-2020/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.20.00549>, <https://pubmed.ncbi.nlm.nih.gov/32749941/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.20.00549> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "León-Castillo A, de Boer SM, Powell ME, et al." ;
  onco:cancers <https://onco.cc/cancers/endometrial-mmr-deficient/>, <https://onco.cc/cancers/endometrial-p53-abnormal/>, <https://onco.cc/cancers/endometrial-pole-ultramutated/> ;
  onco:trials <https://onco.cc/trials/portec-3/> ;
  onco:journals <https://onco.cc/journals/jco/> .